Download free PDF

Duodenal Ulcer Treatment Market Size & Share 2026-2035

Report ID: GMI14360
   |
Published Date: October 2026
 | 
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:

Duodenal Ulcer Treatment Market Size

The duodenal ulcer treatment market was valued at USD 3.3 billion in 2025, is estimated to reach USD 3.47 billion in 2026, and is projected to expand at a 5.1% CAGR (2026–2035), reaching USD 5.42 billion by 2035.

Duodenal Ulcer Treatment Market Key Takeaways

2025 Market Size
$ 3.3 Billion
2026 Market Size
$ 3.47 Billion
2035 Forecast Market Size
$ 5.42 Billion
CAGR (2026–2035)
5.1%
Regional Dominance
Largest Market
North America
Fastest Growing Region
Asia Pacific
Key Players
  • Market Leader: Takeda Pharmaceutical led with over 13.5% market share in 2025.

  • Leading Players: Top 5 players in this market include Takeda Pharmaceutical, AstraZeneca, Eisai, Pfizer, Sun Pharma, which collectively held a market share of 41% in 2025.

The duodenal ulcer treatment market is transitioning from recovery-led demand to structurally sustained growth. Persistent infection-related disease, an expanding older patient population, and broader access to diagnosis are enlarging the treated population, while premium acid-suppression therapies are shifting revenue growth toward higher-value treatment protocols.

GMI Analyst View

Our multi-methodology triangulation across epidemiological bottom-up modeling, aggregated company GI revenue extrapolations, and GMI benchmark data indicates the global duodenal ulcer treatment market reached USD 3.2 billion in 2024. This convergence supports continuity between the market's pre-forecast trajectory and the confirmed 2025 base year.

Duodenal Ulcer Treatment Market Trends, Growth Drivers & GMI Forecast Outlook

The outlook is shaped by a widening pool of patients requiring eradication and acid-suppression therapy, alongside a commercial transition from mature generic therapies toward regimens that address resistance, treatment complexity, and the need for more consistent acid control.

Key Drivers

Driver Evidence signal Market-demand implication GMI forecast condition
Rising *H. pylori* Infection Burden 43.9% global adult prevalence of *H. pylori* (2015-2022) [1] Large, persistent treatment-eligible patient pool sustaining repeated eradication courses and long-term acid suppression prescribing Eradication-therapy revenues expand at above-global rates in North America and Asia Pacific through 2030
Accelerating Geriatric Demographics WHO projects 1.4 billion people aged 60 and older globally by 2030 [2] Expanding cohort with elevated NSAID co-prescription, polypharmacy exposure, and weakened gastric mucosal defense Geriatric-segment revenues post above-global CAGR through 2035
Next-Generation Acid Suppression via P-CABs Vonoprazan received first U.S. FDA approval for *H. pylori* eradication in November 2023 Premium P-CAB prescriptions progressively replace generic PPI protocols, expanding average revenue per treated patient P-CAB-driven premiumization sustains branded-segment revenue growth through forecast period

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

*H. pylori* remains the central clinical driver of ulcer-directed pharmaceutical demand because eradication therapy and acid suppression often must be coordinated rather than prescribed as interchangeable standalone treatments. The organism is implicated in approximately 90% of peptic ulcer disease cases [3]. As resistance complicates conventional regimens, treatment duration, combination intensity, and the use of susceptibility-guided approaches are increasing the value of each treated episode.

Population aging broadens demand beyond infection-led care. Older patients are more likely to receive NSAIDs, manage multiple medicines simultaneously, and experience diminished mucosal resilience, increasing the need for gastroprotection and acute intervention. This shifts demand across outpatient prescriptions, hospital-administered therapies, diagnostic pathways, and follow-on maintenance care.

P-CAB adoption is changing the competitive basis of acid suppression. Faster and more consistent acid control gives vonoprazan-based protocols a differentiated role in eradication and refractory treatment settings, while their branded positioning supports a higher revenue contribution per patient than established generic PPI protocols. The category's trajectory will depend on formulary access, physician familiarity, and the pace at which clinical pathways incorporate newer regimens.

Key Restraints

Restraint Evidence signal Market-demand implication GMI forecast condition
Declining *H. pylori* Prevalence in High-Income Markets Global adult *H. pylori* prevalence has declined 15.9% over three decades [1] Shrinking primary-infection pool in Western Europe and North America caps new-patient volume growth Mature geographies dependent on mix shift toward premium regimens rather than incidence expansion
Antibiotic Resistance and Eradication Failure *H. pylori* eradication fails in approximately 25-40% of patients on clarithromycin-containing regimens [3] High failure rates dampen prescriber confidence; susceptibility-testing requirements create friction Resistance drives demand toward rifabutin-based and vonoprazan-combination regimens at premium pricing
Long-Term Acid Suppression Safety Concerns Prolonged PPI use associated with adverse effects; clinical societies recommend lowest-effective-dose, shortest-duration prescribing Prescriber hesitancy constrains long-term branded-PPI revenues; encourages step-down dosing Net commercial effect is revenue redistribution toward P-CABs rather than contraction of total demand

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Improvements in sanitation, food handling, household conditions, and organized eradication initiatives have reduced transmission in mature healthcare markets. This limits the volume of newly infected patients in parts of North America and Europe, making revenue expansion more dependent on diagnosis, treatment completion, reimbursement, and therapeutic mix than on incidence growth alone.

Antibiotic resistance introduces a practical constraint at the point of care. Where susceptibility testing is unavailable or delayed, clinicians face a narrower set of dependable empirical options, which can slow treatment initiation and increase the likelihood of repeat courses. At the same time, resistance shifts demand toward more complex regimens and diagnostic-supported treatment pathways, creating uneven commercial effects across healthcare systems.

Safety scrutiny also constrains indefinite maintenance use of established acid-suppression therapies. Guidance favoring the lowest effective dose and shortest clinically appropriate treatment period limits the durability of some branded PPI revenue streams. The resulting pressure does not eliminate demand for acid control, but it increases the importance of differentiated therapies and evidence-based treatment selection.

GMI Analyst View

We expect market growth to separate into two distinct commercial tracks: premium protocols centered on differentiated acid suppression and a high-volume generic base serving broad access needs. The balance between those tracks will be determined by reimbursement design, diagnostic capability, and the ability of providers to adapt eradication regimens to local resistance patterns.

Duodenal Ulcer Treatment Market Segment Analysis

By Treatment Type

Pharmacological Treatment

Pharmacological treatment accounted for 91.0% of market revenue in 2025 and is projected to reach USD 4.94 billion by 2035. The duodenal ulcer treatment market remains anchored in drug-based management because acid suppression and eradication therapy address the majority of cases across outpatient, hospital, and homecare settings. Within this category, treatment complexity is increasing as clinicians balance resistance-aware antibiotic selection with demand for more durable acid control.

Duodenal Ulcer Treatment Market Size, by Treatment Type, 2025 & 2035 (USD Million)
Duodenal Ulcer Treatment Market Size, by Treatment Type, 2025 & 2035 (USD Million)

Proton Pump Inhibitors

Proton pump inhibitors represented 46.0% of market revenue in 2025 and are expected to reach USD 2.22 billion by 2035. Their installed clinical base, generic availability, and broad familiarity preserve substantial volume; however, pricing pressure and the migration of selected patients toward P-CABs are gradually changing the class's revenue mix.

H2 Antagonists

H2 antagonists are forecast to generate USD 379 million by 2035 and expand at a 0.5% CAGR (2026–2035). The class retains relevance in milder or episodic acid-related use, but its role is increasingly limited where sustained acid suppression or eradication support is required.

Antibiotics

Antibiotics generated USD 858 million in 2025 and are projected to grow at a 7.6% CAGR (2026–2035). Resistance to traditional regimens is driving a move toward longer, more complex, and more closely managed eradication protocols, making antibiotic selection a larger determinant of treatment costs and clinical outcomes.

Other Drug Classes

Other drug classes generated USD 264 million in 2025 and are expected to reach USD 679 million by 2035. This category includes P-CABs, bismuth compounds, cytoprotective agents, and antacids, with P-CABs supplying the principal source of value expansion as differentiated products gain wider clinical acceptance.

Surgery

Surgery accounted for 9.0% of market revenue in 2025 and is forecast to reach USD 489 million by 2035. Demand is concentrated in refractory disease and severe complications, while therapeutic endoscopy is shifting more appropriate cases toward less invasive management and expanding the importance of specialized procedural capacity.

By Age Group

Adults Aged 18 to 64

Adults aged 18 to 64 generated USD 2.11 billion in 2025 and are projected to expand at a 4.2% CAGR (2026–2035). Infection exposure, NSAID use, and lifestyle-associated risk factors sustain a large treatment base, although demographic momentum is increasingly moving toward older patients with more complex medication profiles.

Duodenal Ulcer Treatment Market Share, by Age Group, 2025
Duodenal Ulcer Treatment Market Share, by Age Group, 2025

Geriatric Patients

Geriatric patients represented 36% of market revenue in 2025 and are projected to reach USD 2.23 billion by 2035. Greater NSAID exposure, polypharmacy, and age-related loss of mucosal protection increase the likelihood of complicated presentations and support demand across both acute-care and maintenance-treatment settings.

By End Use

Hospitals and Clinics

Hospitals and clinics accounted for 58% of market revenue in 2025 and are forecast to reach USD 3.15 billion by 2035. Their leading position reflects responsibility for acute bleeding management, diagnostic endoscopy, biopsy-based testing, and the delivery of intravenous and procedure-supported care for complex cases.

Homecare Settings

Homecare settings represented 22% of market revenue in 2025 and are projected to reach USD 1.19 billion by 2035. Digital prescribing, telemedicine, and outpatient management are reducing barriers between symptom recognition and treatment initiation, particularly for oral eradication and maintenance protocols.

Ambulatory Surgical Centers

Ambulatory surgical centers held a 12% market share in 2025 and are expected to generate USD 651 million by 2035. Their role is expanding as diagnostic and therapeutic endoscopy moves into lower-cost, higher-throughput outpatient environments where appropriate clinical pathways and reimbursement support the shift.

Other End-Use Channels

Other end-use channels accounted for 8% of market revenue in 2025 and are forecast to reach USD 434 million by 2035. Retail and online pharmacies are gaining relevance through generic PPI dispensing, over-the-counter therapies, and community access to maintenance prescriptions.

GMI Analyst View

We see the most consequential segment shift occurring within pharmacological care rather than away from it. Treatment selection is becoming more clinically differentiated, with resistance-aware eradication regimens, premium acid suppression, and care settings that lower access friction reshaping the mix of revenue across the market.

Duodenal Ulcer Treatment Market Regional Analysis

Duodenal Ulcer Treatment Market Share, by Region, 2025 & 2035
Duodenal Ulcer Treatment Market Share, by Region, 2025 & 2035

North America Duodenal Ulcer Treatment Market Analysis

North America accounted for 38% of global revenue in 2025 and is forecast to reach USD 2.06 billion by 2035. The duodenal ulcer treatment market in the region benefits from high pharmaceutical spending, established branded-drug coverage, and early commercialization of P-CAB-based care, although mature infection trends make therapeutic mix and treatment penetration critical to further expansion.

United States

The United States generated USD 1.12 billion in 2025 and is projected to reach USD 1.85 billion by 2035. The market's premium profile is supported by the rollout of vonoprazan-based eradication regimens, concentrated specialist care, payer capacity for branded therapies, and increasing use of resistance-adaptive treatment options.

Canada

Canada generated USD 132 million in 2025 and is forecast to reach USD 216 million by 2035. Population aging and primary-care expansion of testing and eradication pathways support demand, particularly where prevention-oriented management is directed toward higher-prevalence patient populations.

Europe Duodenal Ulcer Treatment Market Analysis

Europe represented 26% of global revenue in 2025 and is expected to reach USD 1.41 billion by 2035. The duodenal ulcer treatment market across Europe is supported by advanced clinical infrastructure and established treatment guidelines, while reference pricing and health technology assessment practices moderate the pace of premium-therapy uptake.

Germany

Germany generated USD 163 million in 2025 and is forecast to reach USD 268 million by 2035. Broad insurance coverage, specialist density, and adherence to susceptibility-informed eradication approaches support comparatively complex treatment pathways and reliable patient access.

United Kingdom

The United Kingdom generated USD 138 million in 2025 and is expected to reach USD 227 million by 2035. Structured primary-care testing and treatment pathways underpin volume, while formulary discipline and generic utilization temper the revenue contribution of branded acid-suppression products.

France

France generated USD 129 million in 2025 and is forecast to reach USD 212 million by 2035. Favorable reimbursement for established gastroenterology products and the role of private specialist care support continued use of premium formulations alongside generic therapies.

Asia Pacific Duodenal Ulcer Treatment Market Analysis

Asia Pacific accounted for 25% of global revenue in 2025 and is projected to grow at a 5.7% CAGR (2026–2035). The duodenal ulcer treatment market in Asia Pacific combines high infection burden, expanding healthcare access, and a diverse commercial environment in which mature P-CAB adoption in selected countries coexists with broad-based generic expansion.

China

China generated USD 264 million in 2025 and is forecast to reach USD 438 million by 2035. Procurement-driven generic pricing expands treatment access, while screening initiatives, hospital-based specialist care, and growing acceptance of premium therapies sustain a layered demand profile.

Japan

Japan generated USD 215 million in 2025 and is expected to reach USD 354 million by 2035. Its established experience with vonoprazan, broad reimbursement for clinically confirmed eradication treatment, and an older patient population reinforce the country's role as a reference market for P-CAB-led care.

India

India generated USD 153 million in 2025 and is projected to expand at a 6.2% CAGR (2026–2035). Growth is supported by improving diagnostic capacity, rising availability of locally manufactured therapies, and an expanding need for accessible acid-suppression and eradication treatment across urban healthcare networks.

South Korea

South Korea generated USD 99 million in 2025 and is forecast to reach USD 164 million by 2035. The country's advanced acid-suppression market and adoption of multiple domestically developed P-CABs position it as an important center for therapeutic innovation and prescriber experience.

Latin America Duodenal Ulcer Treatment Market Analysis

Latin America accounted for 6% of global revenue in 2025 and is projected to reach USD 326 million by 2035. High underlying infection burden and improving access to diagnosis are widening the addressable treatment pool, while price-sensitive payer structures maintain a strong role for generic therapies.

Brazil

Brazil generated USD 88 million in 2025 and is expected to reach USD 145 million by 2035. Expanding private coverage, public gastroenterology capacity, and growing recognition of infection-related gastrointestinal risk are supporting more systematic testing and treatment in urban care networks.

Mexico

Mexico generated USD 61 million in 2025 and is forecast to reach USD 100 million by 2035. Growth is linked to wider community-pharmacy dispensing, improving access to diagnostic endoscopy, and increasing use of specialist care within the private health sector.

Middle East and Africa Duodenal Ulcer Treatment Market Analysis

The Middle East and Africa market generated USD 165 million in 2025 and is projected to reach USD 270 million by 2035. Healthcare infrastructure investment, higher demand for gastroprotective therapies in some labor-intensive economies, and improving diagnostic capacity are strengthening the region's treatment base.

Saudi Arabia

Saudi Arabia generated USD 50 million in 2025 and is forecast to reach USD 82 million by 2035. Investment in primary and specialist care is supporting broader screening and treatment capability, while private providers are expanding access to branded acid-suppression therapies.

United Arab Emirates

The United Arab Emirates generated USD 38 million in 2025 and is expected to reach USD 63 million by 2035. Retail pharmacy development, a large expatriate population, and evolving chronic-disease management initiatives are supporting sustained demand for accessible gastrointestinal care.

South Africa

South Africa generated USD 30 million in 2025 and is forecast to reach USD 49 million by 2035. The coexistence of public generic dispensing and private-sector branded treatment creates a segmented growth profile, with access and payer coverage shaping product mix.

GMI Analyst View

We expect regional opportunity to be defined less by a single global treatment model than by each market's ability to combine diagnosis, reimbursement, and regimen sophistication. Mature markets will monetize innovation through premiumization, while high-growth markets will increasingly determine volume through greater access to standard and emerging therapies.

Duodenal Ulcer Treatment Market Share & Competitive Landscape

The duodenal ulcer treatment market share is distributed across branded gastrointestinal specialists, diversified pharmaceutical companies, and generic manufacturers with strong regional positions. Competitive intensity is increasing as P-CAB commercialization challenges the long-standing role of PPIs, while antibiotic resistance and formulary requirements make clinical evidence, manufacturing reach, and channel execution more consequential.

Takeda Pharmaceutical held a 13.5% market share in 2025, supported by its vonoprazan franchise across Japan and broader Asia Pacific markets, as well as U.S. commercialization through a licensing structure. Its early P-CAB position and depth of clinical experience provide a meaningful advantage as prescribers adopt newer eradication and acid-suppression protocols.

AstraZeneca accounted for 9.5% of market revenue in 2025. Its established esomeprazole franchise retains value in markets where branded gastrointestinal products maintain reimbursement support or formulary standing, though generic competition and the absence of a comparable P-CAB platform create longer-term portfolio pressure.

Eisai represented 6.5% of market revenue in 2025. The company's rabeprazole presence remains relevant in Japan and Asia Pacific, but its competitive position is increasingly exposed to the continued transition from established PPIs toward P-CAB-based treatment strategies.

Generic manufacturers remain central to market access, particularly in Asia Pacific, Latin America, the Middle East, and Africa. Companies with cost-efficient manufacturing, local regulatory expertise, and broad pharmacy distribution are positioned to benefit from rising treatment penetration, while branded competitors must demonstrate differentiation through efficacy, regimen convenience, and specialist adoption.

Recent Industry Developments

Daewoong Pharmaceutical reported in September 2026 that Fexuclue, its fexuprazan hydrochloride P-CAB, achieved a 92% *H. pylori* eradication rate among patients completing a concomitant three-antibiotic regimen in a clinical study. The results provide additional evidence for the use of differentiated acid suppression in resistance-complicated eradication settings [4].

RedHill Biopharma Ltd. and Cumberland Pharmaceuticals Inc. began joint U.S. commercialization of Talicia for *H. pylori* infection treatment in February 2026. The arrangement extends Talicia's commercial reach through a dedicated gastroenterology sales infrastructure and supports broader deployment of a rifabutin-based regimen [3].

Need a specific section of this report?

Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.

Authors:  Monali Tayade, Sampada Kulkarni

Frequently Asked Questions (FAQs):

The Duodenal Ulcer Treatment Market size was estimated at USD 3.3 billion in 2025 and is expected to reach USD 3.47 billion in 2026.
The market is projected to reach USD 5.42 billion by 2035, growing at a CAGR of 5.1% from 2026 to 2035.
North America currently holds the largest share of the Duodenal Ulcer Treatment Market in 2025.
Asia Pacific is projected to be the fastest-growing region during the forecast period.
Some of the major players in Duodenal Ulcer Treatment Market include Takeda Pharmaceutical, AstraZeneca, Eisai, Pfizer, Sun Pharma, Merck, Cipla, GSK, Lupin, Abbott Laboratories, Sanofi, Novartis, Boehringer Ingelheim.

Research methodology, data sources & validation process

This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.

Our 6-step research process

  1. 1. Research design & analyst oversight

    At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.

    Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.

  2. 2. Primary research

    Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.

  3. 3. Data mining & market analysis

    Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.

  4. 4. Market sizing

    Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.

  5. 5. Forecast model & key assumptions

    Every forecast includes explicit documentation of:

    • ✓ Key growth drivers and their assumed impact

    • ✓ Restraining factors and mitigation scenarios

    • ✓ Regulatory assumptions and policy change risk

    • ✓ Technology adoption curve parameter

    • ✓ Macroeconomic assumptions (GDP growth, inflation, currency)

    • ✓ Competitive dynamics and market entry/exit expectations

  6. 6. Validation & quality assurance

    The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.

    Our triple-layer validation process ensures maximum data reliability:

    • ✓ Statistical Validation

    • ✓ Expert Validation

    • ✓ Market Reality Check

Trust & credibility

10+
Years in Service
Consistent delivery since establishment
A+
BBB Accreditation
Professional standards & satisfaction
ISO
Certified Quality
ISO 9001-2015 Certified Company
150+
Research Analysts
Across 20+ industry verticals
95%
Client Retention
5-year relationship value

Verified data sources

  • Trade publications

    Industry journals, trade publications, and specialized media.

  • Industry databases

    Proprietary and third-party market databases

  • Regulatory filings

    Government procurement records and policy documents

  • Academic research

    University studies and specialist institution reports

  • Company reports

    Annual reports, investor presentations, and filings

  • Expert interviews

    C-suite, procurement leads, and technical specialists

  • GMI archive

    13,000+ published studies across 20+ industry verticals

  • Trade data

    Import/export volumes, HS codes, and customs records

Parameters studied & evaluated

Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →

Authors:  Monali Tayade, Sampada Kulkarni
We use cookies to enhance user experience. (Privacy Policy)